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Abstract
Background: This paper describes the rationale and design of the ENVIS-ion Study, which aims to determine
whether low-dose aspirin reduces the development of white matter hyper-intense (WMH) lesions and silent brain
infarction (SBI). Additional aims include determining whether a) changes in retinal vascular imaging (RVI)
parameters parallel changes in brain magnetic resonance imaging (MRI); b) changes in RVI parameters are observed
with aspirin therapy; c) baseline cognitive function correlates with MRI and RVI parameters; d) changes in cognitive
function correlate with changes in brain MRI and RVI and e) whether factors such as age, gender or blood pressure
influence the above associations.
Methods/Design: Double-blind, placebo-controlled trial of three years duration set in two Australian academic
medical centre outpatient clinics. This study will enrol 600 adults aged 70 years and over with normal cognitive
function and without overt cardiovascular disease. Subjects will undergo cognitive testing, brain MRI and RVI at
baseline and after 3 years of study treatment. All subjects will be recruited from a 19,000-patient clinical outcome
trial conducted in Australia and the United States that will evaluate the effects of aspirin in maintaining disability-
free longevity over 5 years. The intervention will be aspirin 100 mg daily versus matching placebo, randomized on
a 1:1 basis.
Discussion: This study will improve understanding of the mechanisms at the level of brain and vascular structure
that underlie the effects of aspirin on cognitive function. Given the limited access and high cost of MRI, RVI may
prove useful as a tool for the identification of individuals at high risk for the development of cerebrovascular
disease and cognitive decline.
Trial Registration: clinicaltrials.gov Identifier: NCT01038583
Background
Cognitive decline and dementia are major causes of mor-
bidity and mortality worldwide and are substantially bur-
densome to the affected persons, their caregivers, and
society in general [1]. Despite extensive research over the
past 20 years, there remain important and formidable
challenges to conducting research, particularly into the
area of prevention. A recent National Institutes of Health
Consensus Development Conference concluded that
large-scale population-based studies and randomised
controlled trials are critically needed to investigate strate-
gies to maintain cognitive function in individuals at risk
or those experiencing cognitive decline [1]. The Aspirin
in Reducing Events in the Elderly (ASPREE) Study is one
such large scale trial and this manuscript describes a neu-
rovascular imaging sub-stud y( E N V I S - i o n )t h a tw i l l
explore the possible mechanisms through which aspirin
may act to influence cognitive function.
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A decline in cognitive abilities is commonly held to be
an inevitable consequence of aging with greater degrees
of decline suggesting the superimposition of progressive
neuropathology. Even in healthy older adults, a small
but definite age-related decrease in performance on
executive function, verbal fluency, verbal memory, and
cognitive speed tasks is evident [2], but the mechanisms
leading to decline are not completely understood [3].
Similarly, reports of the effects of preventive interven-
tions on the trajectories of changes of brain structure
and cognitive performance with aging and early demen-
tia are scarce. Nonetheless, it is clear that in adults over
70 years of age with declining cognitive performance, up
to 15% per year will cross the threshold for the diagno-
sis of clinical dementia [4,5].
Ischaemia of brain white matter may cause cognitive
decline in its own right, but it is also present in the
majority of those with Alzheimer’s (AD). Vascular risk
factors have emerged as important contributors to the
development of AD and to sub-clinical brain infarcts/
ischaemia. This is the most common pathology found in
community-based studies of older adults with cognitive
decline [6,7]. Therefore, vascular disease is an attractive
target for primary preventive therapy.
The question of whether low-dose aspirin might be
protective against cognitive decline, presumably via an
effect on platelet aggregation, remains unanswered. Sev-
eral community-based, prospective studies and a cross-
sectional study have suggested an association of aspirin
treatment with preservation of either episodic memory
or global cognitive performance [8]. Further studies
have contradicted these results and found that long-
term use of aspirin does not provide benefits for cogni-
tion among generally healthy women aged 65 years or
over and may even increase the risk of development of
AD [9,10].
However a number of studies have demonstrated the
effective use of aspirin in the prevention of other condi-
tions such as stroke, coronary heart disease events and
diabetes. Aspirin has been shown to reduce the risk of
serious vascular events (non-fatal myocardial infarction,
non-fatal stroke, or vascular death) by about one quar-
ter, in high-risk patients [11].
Magnetic Resonance Imaging (MRI)
Brain MRI changes correlate with white matter ischae-
mia/infarction and MRI is commonly used to investigate
the underlying mechanisms and predictors of dementia
and cognitive decline [7]. MRI can assess brain structure
changes using volumetric tissue measurements, or inten-
sity-based lesion identification to quantify structural
changes such as hyper-intense white matter lesions
(WMH) or infarcts. The association of greater WMH
volume with poorer cognitive performance remains a
focus of ongoing research. While some studies have
found that WMH presence and volume rather than loca-
tion determines the presence of executive dysfunction in
those who are non-demented, others have specifically
related periventricular WMH to such cognitive dysfunc-
tion [12]. Silent brain infarcts (SBI) are frequently seen
on MRI in healthy older adults and are associated with
dementia incidence and cognitive decline as well as sub-
sequent clinical stroke [13,14]. The Rotterdam Stroke
S t u d yf o u n dt h a tt h ep r e s e n c eo fS B I sa tb a s e l i n em o r e
than doubled the risk of dementia [14]. In addition, the
presence of SBIs at baseline was associated with poorer
initial cognitive performance and a steeper decline in glo-
bal cognition. Also, the incidence of SBI increased mark-
edly with age and a prevalent SBI at baseline strongly
predicted a new silent infarct on the second MRI [15].
The authors concluded that the cardiovascular risk fac-
tors for SBI are similar to those for stroke.
The preventive effects of aspirin on MRI-detected SBI
and WMH have previously been investigated. A study
by Sato et al. found that in patients with non-valvular
atrial fibrillation (NVAF), and perhaps also those in
sinus rhythm, aspirin may reduce SBIs [13]. Fujita et al.
also reported a significant reduction in progression of
WMH over 4 years with aspirin treatment for those
with corrected platelet hyper-aggregability in a study of
older, treated patients compared with age- and WMH-
matched controls [10]
Retinal Vascular Imaging
While brain MRI can potentially provide an efficient
surrogate for cognitive decline and dementia, it is costly
and not widely accessible, making it impracticable for
population screening. Retinal vessels share many fea-
tures with the cerebral vasculature. Hence, should
changes in the two be highly correlated, retinal digital
photography through non-dilated pupils would provide
the opportunity to combine a relatively inexpensive,
rapid, widely available tool with automated analysis to
assess cerebrovascular pathology and inform selection of
those likely to benefit most from further investigation
and preventive therapies.
It is well known that clinically detectable changes in
retinal blood vessels (retinal arteriolar narrowing, arter-
iovenous nicking, microaneurysms, retinal hemorrhages
and cotton wool exudates) are markers of the effects of
chronic hypertension and other vascular processes
[16,17]. Because the retinal circulation can be viewed
non-invasively, it offers a unique insight into the cere-
bral microcirculation in vivo and may allow a greater
understanding of cerebrovascular pathophysiology [16].
Retinal and cerebral arteriolar histopathologies are
highly correlated in those who have died of stroke,
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with WMH and SBI on MRI [18].
Large population-based studies have shown that retinal
vascular changes are associated with subclinical and clini-
cal cerebrovascular disease, including cognitive impair-
ment [16,19]. Other studies have demonstrated that
changes in RVI parameters have been associated with
poorer cognitive performance in people with diabetes
[15,20]. In the Atherosclerosis Risk in Communities
(ARIC) study, RVI changes on photomicrography were
associated not only with incident stroke, but also with
subclinical changes in MRI-defined parameters, including
cerebral infarction, WMH (both sulcal and periventricu-
lar) and atrophy [21-23]. Furthermore, the ARIC study
demonstrated that in patients without a previous stroke,
retinal vascular changes were associated with poorer cog-
nitive function independent of traditional risk factors
[21]. However this study was unable to correlate changes
in cognition with RVI changes over time. Similar studies
have also examined the relationship between RVI
changes and WMH volume [24]. Retinal arterial pathol-
ogy, especially retinal arterial sclerosis and narrowing,
has also been shown to correlate with MRI signs of cere-
bral small-vessel disease in both hypertensive and nor-
motensive subjects [25]. In summary, there are few
studies that have examined the effect of aspirin on MRI-
detected SBI and WMH and RVI parameters and their
relationship to cognition. Importantly, RVI may be a rela-
tively inexpensive, more widely available imaging tool
t h a tc o u l db eu s e dt os c r e e na n dp r e d i c tt h eo n s e ta n d
progression of subclinical cerebrovascular disease.
The ENVIS-ion trial
The ENVIS-ion trial is designed to determine whether;
a) low-dose aspirin reduces the development of
WMH and SBI as assessed by MRI,
b) a reduction in changes in RVI parameters is
observed with low-dose aspirin therapy,
c) changes in RVI parameters parallel changes in
brain MRI,
d) baseline cognitive function correlates with base-
line MRI and RVI parameters,
e) changes in cognitive function correlate with
changes in brain MRI and RVI, and
f) factors such as age, gender, education or blood
pressure influence the above associations.
Methods/design
ENVIS-ion is a multi-center, three-year randomized,
double-blind, placebo-controlled trial in 600 healthy
adults without dementia recruited from general practices
in Melbourne and Canberra, Australia. ENVIS-ion is a
sub-study of the Aspirin in Reducing Events in the
Elderly (ASPREE) clinical trial.
The ASPREE Trial
ASPREE is a large scale, randomized double-blind pla-
cebo-controlled trial of 100 mg enteric-coated aspirin
daily, which is examining the benefits and risks of such
treatment in apparently healthy subjects from Australia
and the United States aged 70 years or more without overt
cardiovascular disease or dementia. Although low-dose
aspirin has been shown to reduce the risk of vascular
events in a wide range of primary and secondary care set-
tings [6,26,27], the benefit of aspirin may be offset by a
variety of adverse effects, such as gastrointestinal and
intracranial hemorrhage; the balance of risks and benefits
has not been established in older subjects.
Subjects
Participants for the ASPREE trial and ENVIS-ion sub-
study will be recruited from general medical practices
and community advertising. General practice participants
will be sent a letter inviting them to participate in the
study. Following preliminary telephone screening, partici-
pants will be included in the study if they are aged 70
years of age or over, not institutionalized, provide
informed consent, and are physically capable of attending
their family physician and for ENVIS-ion, the MRI facil-
ity. Participants in the ASPREE parent study will be
excluded if they have a history of a previous cardiovascu-
lar event, a serious inter-current illness likely to cause
death within the next 5 years, a current or recurrent con-
dition with a high risk of major bleeding, anaemia, an
absolute contraindication to or allergy to aspirin, current
continuous use of aspirin or other anti-platelet drug or
anticoagulant, a systolic blood pressure ≥180 mmHg or
diastolic blood pressure ≥105 mmHg, a history of demen-
tia or a Modified Mini-Mental State Examination (3 MS)
score ≤77, an inability to perform any one of the six Katz
ADL’s [28] independently or with more than ‘a little diffi-
culty’, pill-taking compliance outside the range of 80-
120% during placebo run-in phase, or are currently parti-
cipating in another clinical trial. All ASPREE participants
who have no known contraindications to MRI and can
attend the MRI facility are deemed eligible for entry into
the ENVIS-ion sub-study. MRI contraindications include
a) cardiac pacemaker, b) non-compatible cerebral-aneur-
ysm clip, c) cochlear implant, d) retained metal fragment
in the eye and e) stapedectomy with implant. Treatment
allocation will remain blinded to investigators and sub-
jects until the conclusion of the main ASPREE Study.
Consent and Ethics Approval
All participants will consent separately for the ENVIS-
ion trial after ASPREE trial consent. Protocols (etc.)
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University Health and Research Ethics Committee.
Assessments
All participants will complete a baseline and 3-year follow-
up assessment which will include ASPREE plus additional
ENVIS-ion cognitive testing, MRI and RVI. Additionally,
participants will complete annual ASPREE follow-up visits
comprised of compliance checking by pill count, blood
pressure measurement, reassessment of behavioural traits,
cognitive and quality-of-life tests and biochemical markers
as part of the ASPREE study (Table 1). Retention will be
enhanced through telephone contact quarterly along with
regular newsletter correspondence. The three year follow-
up time was chosen as an optimal time-frame to allow for
the potential impact of treatment and minimize loss to fol-
low-up due to major events such as death.
Data acquisition and storage
Data will be stored securely, anonymized by trial num-
ber, with the trial number - identity key stored
separately.
Study Medications and supplies
An initial box with placebo medication for 4 weeks will be
given to participants at the screening visit to check medi-
cation compliance. If for whatever reason a participant
cannot attend their randomiz a t i o nv i s i ta t4w e e k s ,t h e y
will receive another screening visit and supply of placebo.
Participants in the study will be allocated to one of two
treatments: a) acetylsalicylic acid (ASA) 100 mg, adminis-
tered as an enteric-coated white tablet or b) placebo, an
enteric-coated white tablet with identical appearance. A
100 mg dosage was selected as this is the common inter-
national dose. Enteric coating will ensure that both the
active and placebo medication have an identical taste.
Randomization of drug and placebo will be achieved via
interactive voice recognition software (IVRS) and will be
stratified by primary care practice and age. Subsequent to
the randomization visit each participant will be provided
with 12 months’ supply of study drug; either aspirin or
placebo. At each annual visit each participant will be pro-
vided with the next 12 months supply of their allocated
drug. ENVIS-ion participants will continue receiving ran-
domized therapy for the remaining two years of the
ASPREE main trial after completing their involvement in
the ENVIS-ion study.
Cognitive testing
Cognitive testing for the parent ASPREE trial consists of
i) the Modified Mini-mental State examination as a test
of general intellectual function, on which participants
must score > 77/100 at entry [29]; ii) a single-letter ("F”)
Controlled Oral Word Association test (COWAT),
which gives equivalent information to the longer 3-letter
tests, as a measure of fluency [30]; iii) the Hopkins Ver-
bal Learning Test-Revised as a measure of verbal antero-
grade episodic memory [31]; and iv) an alternative
version of the Digit-Symbol Modalities test as a measure
of psychomotor speed [32]. The Center for Epidemiolo-
gical Studies - Depression Scale (CES-D) is also included
in the ASPREE battery for later analysis as a covariate
[33]. In addition to the cognitive function testing in
ASPREE, ENVIS-ion participants will complete the
Stroop test (Victoria version) as a measure of cognitive
inhibition, and the Color Trails test, which is a non-lan-
guage based test of sequencing, alternation and proces-
sing speed [32,34-36].
The emphasis on aspects of executive functioning
(COWAT, Stroop, Color Trails) and processing speed
(SDMT, Color Trails) reflects the typical neuropsycholo-
gical pattern seen with cognitive impairment due to
Table 1 Measurement schedule for the participants of the ENVIS-ion trial.
Recruitment, Screening &
Baseline
Annualreview
(1 yr)
Annualreview
(3 yr)
Annualreview
(5 yr)
ENVIS-ion study
Brain MRI & RVI X X
Additional cognitive function tests
a XX
ASPREE parent study
Inclusion/exclusion criteria; informed
consent
X
Cognitive function tests
b XX X X
Demographics & physical measures
c XX X X
Blood pressure & cardiovascular
biomarkers
d
XX X X
Health behaviors & lifestyle measurements
e XX X X
a Stoop test (Victoria version) & Color Trails test
b 3 MS, Digit Symbol Modalities test, COWAT, and Hopkins Verbal hearing test
c Includes first language, level of
education, height, weight, abdominal circumference, family history & co-morbidity;
d Includes total cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglycerides, C-
Reactive Protein, Hemoglobin, fasting glucose & creatinine;
e Includes physical activity, smoking history & alcohol use, SF-36 & IADL
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study. The choice of test battery is based on the neurop-
sychological batteries suggested for assessment of vascu-
lar cognitive impairment [38]. Assessors will undergo
standard training and assessment of the administration
of tasks and this will be recertified on an annual basis
and if the number of assessments falls below three in a
three month period.
Magnetic Resonance Imaging
A non-contrast MRI examination will be performed on
all participants at either the Canberra or Alfred Hospi-
tals at baseline and 3 years later using 1.5 Tesla Siemens
and GE machines respectively. A number of standar-
dized MRI Brain sequences will be acquired to allow
morphologic, microstructure and functional assessment.
First, a volumetric 3D T1-weighted sequence is used to
obtain high resolution anatomical information. This is
followed by the FLAIR and T2 sequences used to assess
inflammation and signal alteration in brain tissues. A
Gradient Echo T2-weighted (GE T2) or Susceptibility
Weighted Imaging (SWI) sequence will be used to
detect micro-hemorrhages. Where technically possible,
Arterial Spin Labeling (ASL) will be used to quantify
brain perfusion without the need to use exogenous con-
trast agents. Finally, Diffusion Tensor Imaging (DTI)
data will be acquired to evaluate underlying neural tis-
sue diffusion properties, permitting assessment of com-
plex brain microstructure (e.g. axonal loss in white
matter tracts).
MRI analyses will be performed at the Dementia Colla-
borative Research Centre Imaging Laboratory in Can-
berra. All assessment will be conducted blinded to
treatment allocation and participant data. Standard pre-
processing for all volumetric images will follow best prac-
tice that has been developed for such studies with large
numbers of participants [39]. This includes; 1) N3 B0
MRI nonlinear intensity distortion correction, between-
scan intensity normalization and registration to a popula-
tion-specific model that is then later matched to the
ICBM model of cortical anatomy; 2) model-based seg-
mentations of whole brain, ventricular, lobar and hippo-
campal volumes; 3) white matter/grey matter (WM/GM)
segmentation: a multi-spectral segmentation utilizing all
acquired data types will provide a good measure of the
CSF and WM/GM volumes, and consequently, accurate
atrophy measures as well as lobar WM/GM differences;
4) nonlinear registration of the EPI T2 from the func-
tional scans to the gradient echo volumetric T2. The GE
T2 will then be matched to the volumetric T1 and then
to the ICBM model using an iterative nonlinear registra-
tion to reduce within-group subject differences at time
steps.
Calculations will be made from the scans regarding
WMH with respect to their total volume and rate of
change in volume. The presence or absence of sub-cortical
infarction will be determined and the total brain volume
calculated. The presence and count of cerebral micro-
bleeds will be determined from the GE T2 and SWI data
and brain tissue perfusion will be assessed from the ASL
scans. Volumetric change of structures including the hip-
pocampus and ventricles will be assessed via the auto-
mated comparison of each of the individuals to average
models of anatomy.
Retinal Vascular Imaging
T w oc o l o rr e t i n a lp h o t o g r a p h s ,c e n t e r e do nt h eo p t i c
disc (ETDRS standard fields 1 (Figure 1)) and macula
(standard field 2), respectively, will be taken from each
eye of the participant. The photographs will be taken
after 5 minutes of dark adaption, without pharmacologi-
cal pupil dilation, using a Canon NMR 45 digital fundus
camera. Photographers are certified for quality of mea-
surement by the central reporting group prior to the
commencement of the study.
RVI images will be sent to the core analysis laboratory at
the Retinal Vascular Imaging Centre in Melbourne for ana-
lysis by trained graders. Photographs centered on the optic
disc of each eye will be examined using standard compu-
ter-assisted retinal analysis software that was initially devel-
oped for the ARIC study [40]. The grading approach
measures retinal vessel diameters and combines the mea-
surements into central retinal arteriolar and venular
equivalents (CRAE and CRVE) with formula adjusting for
branching, following the Parr and Hubbard formula [40].
The analysis software has been modified and improved,
and used in a number of studies including the Australian
Diabetes, Obesity and Lifestyle Study (AusDiab) and the
Blue Mountains Eye Study (BMES) in Australia [41]. The
graders will use an automated system to measure the cali-
bers of all arteriolar and venular branches crossing a zone
defined as the region between 1/2 and 1 disc diameter
from the optic disc. The grader will monitor the whole
process, carefully select appropriate vessel regions for cali-
ber measurement and correctly identify small arteriolar
and venular branches. Correction factors are used in analy-
sis of the measured values of absolute vessel caliber. All
grading will be conducted blinded to treatment allocation.
Technically unsatisfactory scans are typically not improved
by re-photography, and will not be included in the analysis.
The qualitative presence of focal retinal arteriolar nar-
rowing, arteriovenous nicking, arteriolar wall opacity
(“silver wiring”) and the presence of retinopathy lesions
will also be assessed. Each lesion is classified as definite,
questionable/probable, or none in each of the retinal
photographic fields.
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Approximately 300 participants each from Melbourne
and from Canberra, Australia will be enrolled in ENVIS-
ion. The sample size calculations were based on a) a
pilot study of 144 older adults, in which acceptance of
MR imaging was 88%, and which produced MR imaging
estimates of change in relevant structural brain para-
meters over a two-year period; b) rate of change of
WMH over 3 years from the PROSPER trial of adults
aged 70 years or over [42]; and c) cautious interpreta-
tion of the report by Sato et al., in which treatment with
around 300 mg/day of aspirin over one year reduced
incident SBIs on MRI from 20.6% to 9.6% in 150 partici-
pants with non-valvular atrial fibrillation (i.e. a relatively
higher risk group than in ENVIS-ion) [13,43]. Based on
power calculations related to the primary hypothesis, we
conservatively estimate the need for at least 230 per
treatment arm to achieve a statistical power of 0.9 to
show a relative risk reduction of 15% with a 2-sided a
of 0.05.
Statistical analysis
Group descriptive statistics will be used to define the
baseline characteristics of subjects randomized to aspirin
and placebo groups. Continuous variable changes will be
normalized prior to analysis and non-parametric meth-
ods will be used where required. Changes in continuous
variables for both MRI and RVI over three years will be
analyzed using analysis of covariance (ANCOVA) adjust-
ing for baseline values (Aims 1,2 & 5). Chi-square and
logistic regression analysis will be used to assess changes
in categorical variables. Correlation and regression ana-
lysis will be used to determine the association between
changes in MRI and RVI measures and the association
of baseline cognitive measures with MRI and RVI para-
meters (Aims 3 & 4). Generalized linear models will be
developed to determine whether age, gender, education,
previous aspirin use and hypertensive status modify the
treatment effects on MRI and RVI outcome measures
(Aim 6).
Discussion
While the ASPREE trial will address the question of
whether low-dose aspirin can prevent death or the onset
of disability, including dementia and cognitive decline,
over a 5-year period in people 70 years and over, the
ENVIS-ion sub-study provides a unique opportunity to
examine whether regular low-dose aspirin reduces the
rate of increase of brain MRI-measured WMH and SBI
volumes. In addition, the trial will also investigate if
Figure 1 Retinal Vascular Imaging measurement of Retinal Calibre.
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over 3 years and explore the value of MRI and RVI in
assessing and defining vascular changes and cognitive
function. The ASPREE trial and the ENVIS-ion sub-
study target healthy adults over the age of 70 years liv-
ing in the community: this large and growing segment
of the population needs to be the focus of specific atten-
tion as cognitive function will be a major determinant of
their overall health status and the extent of assistance
that will be required during their projected average life
expectancy of 10 to 15 years [6].
Undeniably, although we currently deploy more
resources for those with greater morbidity, it is poten-
tially healthy older adults who have most to gain from
preventive strategies. The thorough evaluation of an
inexpensive, widely available intervention such as low-
dose aspirin for the prevention of dementia and cogni-
tive decline is timely in the context of the ever-increas-
ing numbers of older people and the associated rising
incidence of dementia.
The unique features of the ENVIS-ion study lie in the
combination of the extensive but targeted nature of the
cognitive assessment, combined with the detailed assess-
ment of the brain and retina. Evidence shows that ret-
inal micro-vascular changes reflect cerebral micro-
vascular changes in aging, as well as in diseases such as
vascular dementia and stroke [44]. Given the limited
access and high cost of MRI, and the increasing penetra-
tion of RVI into routine ophthalmic and optometric
practice, RVI may prove useful as a tool for the identifi-
cation of individuals at high risk for the development of
cerebrovascular disease and cognitive decline, who can
then be targeted for intensive risk factor reduction, pos-
sibly including aspirin therapy.
The ENVIS-ion study will add to the current knowl-
edge in the field by identifying whether aspirin treat-
ment can influence the development and progression of
white matter hyper-intensities which in-turn influence
cognitive function. Importantly, it will determine
whether retinal vascular imaging, a much less expensive
approach, may be an alternative approach to MRI mea-
surement. Clinically this mayr e s u l ti nal o wc o s ta l t e r -
native to identify whether older people who may benefit
from aspirin therapy, should be treated. Whilst there are
a number of ongoing trials exploring the changes in
white matter lesions and associations with cognitive
function in ageing, none are looking at the association
between retinal vascular imaging and MRI changes over
time and their relationship with cognitive function [45].
A potential limitation of the study is that it will only
provide information on people who reach the age of 70
years free from manifest cardiovascular disease and can-
cer, although most individuals will probably have subcli-
nical atherosclerosis. However, given the increases in
lifespan projected over the future decades, this is likely
to represent an ever-increasing number of older people.
The three year follow-up may be considered as a limita-
tion; however it may also be optimal for the effects of
aspirin to be demonstrable on the vasculature while
minimizing potential loss to follow-up.
Lifestyle or pharmacological interventions that mini-
mize decline in cognitive performance are urgently
required. Aspirin is an appealing therapeutic candidate
given its universal availability, community acceptance
and low cost, all of which ensure equity and would facil-
itate community uptake. Equally, analyses of the brain
and automated retinal imaging results from this trial
will inform guidelines for health professionals where
currently uncertainty exists. The ENVIS-ion trial will
significantly inform global efforts to maximize our abil-
ities to “maintain the brain” and, in addition, may
improve the understanding of the mechanisms at the
level of brain and vascular structure that underlie the
effects of aspirin on cognitive function.
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